Oleander Phoenix Biotechnology, Inc. executes a share exchange agreement with Nerium Biotechnology, Inc. by which Nerium Biotechnology acquires all the Latin American operations of Phoenix. Posted on December 2006June 2022 by Carlos Torres 06 Dec Publication: Oleandrin-mediated oxidative stress in human melanoma cells. Newman RA, Yang P, Hittelman WN, Lu T, Ho DH, Ni D, Chan D, Vijjeswarapu M, Cartwright C, Dixon S, Felix E, Addington C. J Exp Ther Oncol. 2006;5(3):167-81. Phoenix enters into contract with Quintiles, Inc. to act as Clinical Research Organization for “An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients” to be conducted at M. D. Anderson Cancer Center.